This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday – Almonty Indus (NASDAQ:ALM), Adagene (NASDAQ:ADAG)

Aug 6, 2025
this-palvella-therapeutics-analyst-begins-coverage-on-a-bullish-note;-here-are-top-5-initiations-for-wednesday-–-almonty-indus-(nasdaq:alm),-adagene-(nasdaq:adag)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • HC Wainwright & Co. analyst Brandon Folkes initiated coverage on Indivior PLC INDV with a Buy rating and announced a price target of $28. Indivior shares closed at $21.80 on Tuesday. See how other analysts view this stock.
  • DA Davidson analyst Griffin Bryan initiated coverage on Almonty Industries Inc. ALM with a Buy rating and announced a price target of $7. Almonty shares closed at $4.15 on Tuesday. See how other analysts view this stock.
  • HC Wainwright & Co. analyst Douglas Tsao initiated coverage on Rapport Therapeutics, Inc. RAPP with a Buy rating and announced a price target of $31. Rapport Therapeutics shares closed at $14.43 on Tuesday. See how other analysts view this stock.
  • Raymond James analyst Ryan Deschner initiated coverage on Palvella Therapeutics, Inc. PVLA with an Outperform rating and announced a price target of $54. Palvella Therapeutics shares closed at $37.52 on Tuesday. See how other analysts view this stock.
  • Leerink Partners analyst Daina Graybosch initiated coverage on Adagene Inc. ADAG with an Outperform rating and announced a price target of $7. Adagene shares closed at $1.8992 on Tuesday. See how other analysts view this stock.

Considering buying PVLA stock? Here’s what analysts think:

Trending Investment Opportunities

Read This Next:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Leave a comment